1. INTRODUCTION
===============

Glioblastoma multiforme ([gbm]{.smallcaps}) is a World Health Organization grade [iv]{.smallcaps} astrocytoma and the most common and aggressive primary brain tumour [@b1-co14_3p110]. In North America, the estimated age-adjusted incidence of [gbm]{.smallcaps} is 3.0 per 100,000 population [@b1-co14_3p110]. It occurs more commonly in males (male:female ratio of approximately 3:2) and is typically diagnosed in patients in their sixth or seventh decade.

The preoperative imaging modality of choice is gadolinium-enhanced magnetic resonance imaging ([mri]{.smallcaps}). Although contrast-enhanced [mri]{.smallcaps} may indicate a discrete border, [gbm]{.smallcaps} tumours are characterized by extensive microvascular infiltration and rapid proliferation. Based on distinct pathogenetic features, at least two subtypes of [gbm]{.smallcaps} can be defined. Primary (*de novo*) glioblastoma is more common in older patients (mean age: 55 years) [@b2-co14_3p110] and typically harbours overexpression or mutation of epidermal growth factor receptor, genetic losses on chromosome 10, p16 or p19 alterations, or loss of the tumour suppressor protein phosphatase and tensin homologue [@b3-co14_3p110]--[@b6-co14_3p110]. Secondary glioblastoma develops more slowly from a lower-grade tumour and typically occurs in younger patients (≤45 years). Genetic alterations may include *TP53* mutation or overexpression of platelet-derived growth factor receptor α [@b7-co14_3p110].

Although imaging techniques and multimodal treatment strategies have improved since the mid-1980s, little impact has been made on the ultimate prognosis of [gbm]{.smallcaps}. A population-based cohort study of all Ontario Cancer Registry cases of [gbm]{.smallcaps} identified between 1982 and 1994 found that the median survival of patients receiving radiotherapy ([rt]{.smallcaps}) and surgery was 11 months; median survival with surgery alone was 3 months [@b8-co14_3p110]. An analysis of the Alberta Cancer Registry database of [gbm]{.smallcaps} patients diagnosed between 1975 and 1991 reported that only 1.8% survived at least 3 years [@b9-co14_3p110]. A decade later, an analysis by the Glioma Outcomes Project of cases diagnosed between 1997 and 2001 reported a median survival of 40.9 weeks for newly-diagnosed patients with [gbm]{.smallcaps} [@b10-co14_3p110]. An analysis of the Surveillance, Epidemiology, and End Results database found no significant improvement in the [gbm]{.smallcaps} survival rate after the 1980s [@b1-co14_3p110].

The principal reasons for poor outcome in [gbm]{.smallcaps} are the high rates of recurrence and of resistance to chemotherapy. Choucair *et al.* estimated that more than 90% of gliomas recur, typically at the site of the original tumour [@b11-co14_3p110]. Numerous chemotherapy regimens, administered either before [rt]{.smallcaps} or adjuvantly, have been investigated, but they have had little impact on patient outcomes [@b12-co14_3p110]--[@b16-co14_3p110]. Prognosis is affected by the histologic features of the tumour, patient age, and performance status [@b17-co14_3p110],[@b18-co14_3p110].

Standard treatment for [gbm]{.smallcaps} was significantly altered following the results of a large phase [iii]{.smallcaps} trial conducted by the European Organization for the Research and Treatment of Cancer ([eortc]{.smallcaps}) and the National Cancer Institute of Canada [@b19-co14_3p110]. The [eortc ncic ce]{.smallcaps}3 trial randomized 573 newly-diagnosed glioblastoma patients to [rt]{.smallcaps} alone (2 Gy, 5/7-day schedule for 6 weeks, 60 Gy total), or to [rt]{.smallcaps} in combination with the oral alkylating agent temozolomide. The temozolomide dose was 75 mg/m^2^ daily during [rt]{.smallcaps}, followed by adjuvant temozolomide 150--200 mg/m^2^ daily in a 5/28-day schedule for 6 cycles. With the [rt]{.smallcaps}--temozolomide combination, 2-year survival was 26.5% as compared with 10.4% with [rt]{.smallcaps} alone. Median survival was 12.1 months and 14.6 months respectively. As a result, concurrent [rt]{.smallcaps} and temozolomide, followed by 6 monthly cycles of adjuvant temozolomide, became the new standard of care for patients newly diagnosed with [gbm]{.smallcaps}.

However, numerous questions remain about how to identify patients who will be more likely to respond to treatment and how to optimize a multimodal approach to patient management. The recommendations that follow were developed by a multidisciplinary panel of Canadian neuro-oncologists, neurosurgeons, and radiation oncologists---based on level 1 evidence where possible---as a guide to optimizing the management of patients with [gbm]{.smallcaps}.

2. THE RECOMMENDATIONS
======================

2.1 General Principles
----------------------

### Recommendation 1

Management of patients with [gbm]{.smallcaps} should be highly individualized and should take a multidisciplinary approach involving neuro-oncology, neurosurgery, radiation oncology, and pathology, to optimize treatment outcomes. The care path of [gbm]{.smallcaps} is complex and requires the cooperation and integration of services from multiple health care specialties and institutions so as to avoid unacceptable wait times.

All surgeries should be presented at a weekly brain tumour conference, with the neurosurgeon, radiation oncologist, and neuro-oncologist present. Ideally, for each case, the multidisciplinary team should review the patient's clinical status, neuroimaging, and histopathologic findings to determine the optimal treatment approach.

It is recommended that the neurosurgeon inform the patient of the diagnosis. Patients and caregivers should be kept informed of the progress of treatment at every stage. Patients should receive a brain tumour information package to help them understand [gbm]{.smallcaps} and the treatment options, and to better inform their decision-making. Patient consent should be obtained for tumour banking.

2.2 Pathology
-------------

Specific, unique genetic changes are common in astrocytic tumours. An estimated one half of grades [ii]{.smallcaps}--[iii]{.smallcaps} infiltrating astrocytomas have detectable mutations in the *TP53* tumour suppressor gene [@b20-co14_3p110]. Loss of heterozygosity on chromosomes 1p and 19q is usually associated with oligodendroglioma, but sometimes occurs in oligoastrocytomas. Loss of heterozygosity is associated with increased sensitivity to pro-carbazine--lomustine--vincristine chemotherapy [@b21-co14_3p110]. In that regard, two [eortc]{.smallcaps} phase [ii]{.smallcaps} trials reported that first-or second-line temozolomide produced a high response rate in patients with recurrent or progressive oligoastrocytoma or oligodendroglioma [@b22-co14_3p110],[@b23-co14_3p110]; response was associated with 1p and 19q loss [@b24-co14_3p110]. Glioblastoma multiforme is more chemoresistant, and genetic markers do not appear to have comparable prognostic significance [@b25-co14_3p110]. Of particular importance, however, is O[@b6-co14_3p110]-methylguanine [dna]{.smallcaps} methyltransferase ([mgmt]{.smallcaps}), a repair protein that removes methyl adducts and transfers them to an internal cysteine residue [@b26-co14_3p110]. Because the O[@b6-co14_3p110] position is one of the targets of alkylating chemotherapeutic agents, [mgmt]{.smallcaps} activity enhances tumour resistance by repairing cytoxic damage. Conversely, tumour sensitivity is enhanced if [mgmt]{.smallcaps} is silenced through hypermethylation of the CpG islands in the promoter region [@b27-co14_3p110]--[@b29-co14_3p110].

A number of studies have indicated that [mgmt]{.smallcaps} promoter methylation is predictive of a good response to alkylating agents such as 1,3-bis(2-chloroethyl)-1-nitrosourea ([bcnu]{.smallcaps}) and cyclophosphamide [@b30-co14_3p110],[@b31-co14_3p110]. Following the phase [iii]{.smallcaps} study of combined [rt]{.smallcaps} and temozolomide [@b19-co14_3p110], Hegi *et al.* analyzed the [mgmt]{.smallcaps} promoter methylation status of 206 evaluable patients [@b32-co14_3p110]. In 92 tumours (44.7%), [mgmt]{.smallcaps} promoter methylation was detectable. Median survival was 18.2 months in patients with promoter methylation as compared with 12.2 months in those without methylation, and median survival was 21.7 months in [rt]{.smallcaps}--temozolomide-treated patients with promoter methylation. In the subgroup of patients with promoter methylation, 2-year survival was 46% in the [rt]{.smallcaps}--temozolomide group as compared with 22.7% in patients treated with [rt]{.smallcaps} alone ([Table I](#tI-co14_3p110){ref-type="table"}). In the subgroup of patients without promoter methylation, median survival was only marginally superior with combined [rt]{.smallcaps}--temozol-omide than with [rt]{.smallcaps} alone (12.7 months vs. 11.8 months); 2-year survival was 13.8% as compared with \<2% respectively.

Temozolomide is a recommended treatment for newly-diagnosed [gbm]{.smallcaps} and for recurrent high-grade gliomas. Although [mgmt]{.smallcaps} methylation status appears to be a prognostic factor for increased survival and possibly for better response to temozolomide, a prospective study is required before promoter hyper-methylation can be used as a guide to treatment decisions in [gbm]{.smallcaps}.

### Recommendation 2

The molecular genetic determination of brain tumours is becoming increasingly important, enabling more accurate diagnosis and prognosis. Sufficient tissue should be obtained during surgery for cytogenetic analysis and, whenever feasible, for tumour banking. The preliminary pathology report should be available within 48 hours post surgery; the final report should be completed within 8 working days post surgery.

2.3 Surgery
-----------

### Recommendation 3

Surgery is an integral part of the treatment plan, to establish a histopathologic diagnosis and to achieve safe maximal tumour resection, which may improve clinical signs and symptoms.

A gross total resection, if achievable, is advised in any patients with a primary or recurrent malignant glial tumour if the surgery can be performed without significant risk to the patient. Simpson *et al.* analysed data from 645 [gbm]{.smallcaps} patients in three prospective Radiation Therapy Oncology Group trials [@b33-co14_3p110]. Surgery consisted of total resection (19%), partial resection (64%), or biopsy only (17%). Median survival was 11.3 months for total resection, 10.4 months for partial resection, and 6.6 months for biopsy.

### Recommendation 4

The preoperative imaging modality of choice is [mri]{.smallcaps} with gadolinium as the contrast agent. Other imaging modalities, such as positron emission tomography with \[^18^F\]-fluoro-deoxy-[d]{.smallcaps}-glucose, may also be considered in selected cases [@b34-co14_3p110]. Postoperative imaging ([mri]{.smallcaps} or computed tomography) is recommended within 72 hours of surgery to evaluate the extent of resection.

2.4 Radiotherapy
----------------

The use of adjuvant external-beam [rt]{.smallcaps} is well established in the postoperative treatment of [gbm]{.smallcaps}. A pooled analysis of six randomized trials by Cancer Care Ontario reported a significant survival benefit favouring postoperative [rt]{.smallcaps} as compared with no [rt]{.smallcaps} (risk ratio: 0.81) [@b35-co14_3p110],[@b36-co14_3p110]. Overall, median survival is approximately 36--48 weeks with adjuvant [rt]{.smallcaps} as compared with 14--22 weeks with surgery alone [@b37-co14_3p110]--[@b39-co14_3p110].

External-beam [rt]{.smallcaps} is generally administered over 5--6 weeks, delivering a total dose of 50--60 Gy in 1.8- to 2.0-Gy fractions [@b40-co14_3p110]. Doses above 60 Gy and boost [rt]{.smallcaps} do not appear to influence survival [@b40-co14_3p110],[@b41-co14_3p110].

Alternative forms of fractionation have been investigated. Accelerated fractionation delivers standard fraction sizes more frequently (for example, 2 or 3 times daily) to reduce the overall treatment time. Several studies have reported no increased survival, although no increased toxicity was found [@b42-co14_3p110]--[@b44-co14_3p110]. This approach may be an option for selected patients (such as the elderly), but additional study is needed.

Hyperfractionation, which delivers a higher total radiation dose in a larger number of smaller fractions, showed no improvement in time to tumour progression or survival [@b45-co14_3p110],[@b46-co14_3p110].

Radiotherapy should be initiated within 4 weeks of surgery.

### Recommendation 5

Postoperative external-beam [rt]{.smallcaps} is recommended as standard therapy for patients with [gbm]{.smallcaps}. The recommended dose is 60 Gy in 2-Gy fractions [@b35-co14_3p110],[@b36-co14_3p110]. The recommended clinical target volume should be identified with gadolinium-enhanced T1-weighted [mri]{.smallcaps}, with a margin in the order of 2--3 cm, given that most recurrences will occur within a few centimetres of the tumour mass [@b47-co14_3p110],[@b48-co14_3p110]. Target volumes should be determined based on a postsurgi-cal planning [mri]{.smallcaps}. A shorter course of radiation may be considered for older patients with poor performance status [@b49-co14_3p110],[@b50-co14_3p110].

2.5 Chemotherapy
----------------

Glioblastoma multiforme has been viewed as a chemoresistant tumour, and the nitrosoureas, the traditional mainstays of treatment, have had modest efficacy, but are associated with significant toxicity [@b39-co14_3p110]. Most studies were reported decades ago, but a recent phase [ii]{.smallcaps} trial evaluated [bcnu]{.smallcaps} 80 mg/m^2^ on days 1--3 every 8 weeks (maximum 6 cycles) in 40 patients with recurrent [gbm]{.smallcaps} who had undergone surgery and RT[@b51-co14_3p110]. The median time to progression was 13 weeks; the 6-month progression-free survival ([pfs]{.smallcaps}) was 17.5%. Significant side effects included reversible hematologic toxicities and chronic hepatic and pulmonary toxicity.

### Recommendation 6

During [rt]{.smallcaps}, temozolomide 75 mg/m^2^ should be administered concurrently for 42 days [@b35-co14_3p110]. Temozolomide should be given approximately 1 hour before [rt]{.smallcaps}, and at the same time on the days when no [rt]{.smallcaps} is scheduled (weekends).

Whether the clinical benefit of this combination is attributable in part to the radiosensitizing effects of temozolomide is unclear. To date, four *in vitro* studies have suggested a radiosensitizing effect with tem-ozolomide for some cancer cell lines [@b52-co14_3p110]--[@b55-co14_3p110], but additional research is needed.

### Recommendation 7

Adjuvant temozolomide 150 mg/m^2^, in 5/28-day schedule, is recommended for cycle 1, followed by 5 cycles if well tolerated. Additional cycles may be considered in partial responders or in those with continuing radiologic improvement. The dose should be increased to 200 mg/m^2^ at cycle 2 if well tolerated. Weekly monitoring of blood count is advised during chemoradiation therapy in patients with a low white blood cell count. *Pneumocystis carinii* pneumonia has been reported, and prophylaxis should be considered [@b56-co14_3p110].

### Recommendation 8

For patients with stable clinical symptoms during [rt]{.smallcaps}--temozolomide, completion of 3 cycles of adjuvant therapy is generally advised before a decision is made about whether to continue treatment. In the first few weeks or months following completion of [rt]{.smallcaps}, [mri]{.smallcaps} is not reliable to assess true progression. Evidence of progression outside the [rt]{.smallcaps} field is indicative of true progression. A longer duration may be considered in patients who show continuous improvement on therapy.

2.6 Recurrent GBM
-----------------

### Recommendation 9

Selected patients with recurrent [gbm]{.smallcaps} may be candidates for repeat resection when the situation appears favourable based on an assessment of individual patient factors such as medical history, functional status, and location of the tumour [@b57-co14_3p110],[@b58-co14_3p110]. Entry into a clinical trial is recommended for patients with recurrent disease.

### Recommendation 10

The optimal chemotherapeutic strategy for patients who progress following concurrent chemoradiation has not been determined. Therapeutic and clinical-molecular studies with quality of life outcomes are needed [@b35-co14_3p110].

For patients not receiving chemotherapy at the time of progression, re-challenge with temozolomide to deplete [mgmt]{.smallcaps} might be attempted, but clinical data on this strategy are lacking.

Some preliminary data suggest that novel dose-intense schedules may provide some benefit. Khan *et al.* reported a 6-month [pfs]{.smallcaps} of 19% with temozolomide 75 mg/m^2^ in a 42/70-day schedule [@b59-co14_3p110]. In a small phase [ii]{.smallcaps} study by Wick *et al.*, the 6-month [pfs]{.smallcaps} was 48% with temozolomide 150 mg/m^2^ administered in a 7-day on / 7-day off schedule [@b60-co14_3p110]. Although the findings are promising, additional phase [ii]{.smallcaps} studies are required before the foregoing dosing regimens can be recommended.

A number of chemotherapeutic agents, including nitrosoureas, carboplatin, etoposide, irinotecan, and imatinib [@b61-co14_3p110]--[@b64-co14_3p110], have been used as salvage therapy either alone or in combination. Additional trials with a variety of agents are underway, but preliminary results from single-agent studies have been disappointing. [Table II](#tII-co14_3p110){ref-type="table"} summarizes phase [ii]{.smallcaps} studies in [gbm]{.smallcaps}.

For patients who progress on temozolomide, combination therapy may be possible; several recent trials have evaluated various temozolomide combinations ([Table II](#tII-co14_3p110){ref-type="table"}). For example, the efficacy of bolus temozolomide 130 mg/m^2^ followed by 70 mg/m^2^ every 12 hours for 5 days, plus cisplatin 75 mg/m^2^, was evaluated in 50 patients with recurrent [gbm]{.smallcaps} [@b65-co14_3p110]. Among the 49 evaluable patients, 1 patient achieved a complete response, and 9 achieved partial responses. The 6-month [pfs]{.smallcaps} was 34%; the 12-month [pfs]{.smallcaps} was 4%. Overall survival was 11.2 months. The most common grade 3--4 toxicity was granulocytopenia, which occurred in 8% of cycles.

3. CONCLUSIONS
==============

Surgery followed by [rt]{.smallcaps} still represents the primary approach to the treatment of [gbm]{.smallcaps}. The addition of temozolomide chemotherapy to the standard of care has significantly increased the proportion of patients who survive more than 2 years. However, additional progress still needs to be made, because almost one half of [gbm]{.smallcaps} patients will not survive the first year after surgery. Additional research is needed to build on recent clinical gains and to focus on new drug combinations or therapies that could potentially further improve outcomes in patients with [gbm]{.smallcaps}.

Figures and Tables
==================

###### 

Effect of methylation status of methylguanine DNA methyltransferase ([mgmt]{.smallcaps}) promoter on progression-free survival ([pfs]{.smallcaps}) and overall survival ([os]{.smallcaps}) in patients receiving radiotherapy plus temozolomide ([tmz]{.smallcaps}) versus radiotherapy (RT) alone[a](#tfn1-co14_3p110){ref-type="table-fn"}

  *Clinical endpoint*       *TMZ + RT (*n*=106)*   *RT (*n*=100)*
  ------------------------- ---------------------- ----------------
  Methylated MGMT (*n*)     46                     46
   6-Month PFS              47.8                   68.9
   2-Year OS                22.7                   46.0
  Unmethylated MGMT (*n*)   54                     60
   6-Month PFS              35.2                   40.0
   2-Year OS                \<2                    13.8

Adapted from reference [@b32-co14_3p110].

###### 

Phase [ii]{.smallcaps} studies in recurrent glioblastoma multiforme

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Reference*                          *Regimen*                                                                                                               *Patients (*n*)*   *6-Month[pfs]{.smallcaps}(%)*
  ------------------------------------ ----------------------------------------------------------------------------------------------------------------------- ------------------ ------------------------------------------------------------
  Yung *et al.*[@b65-co14_3p110]       [tmz]{.smallcaps} 150--200 mg/m^2^ daily, 5/28-day schedule\                                                            225                21\
                                       vs. [pcb]{.smallcaps} 125--150 mg/m^2^, 28/56-day schedule                                                                                 8

  Groves *et al.*[@b66-co14_3p110]     [tmz]{.smallcaps} 150--200 mg/m^2^, 5/28-day schedule + marimastat 50 mg, days 8--28 × 2 cycles                         44                 39

  Jaeckle *et al.*[@b67-co14_3p110]    [tmz]{.smallcaps} 150--200 mg/m^2^, 5/28-day schedule + *cis-*retinoic acid 100 mg/m^2^, 21/28-day schedule             40                 32

  Brandes *et al.*[@b68-co14_3p110]    [tmz]{.smallcaps} 130 mg/m^2^ bolus, [tmz]{.smallcaps} 70 mg/m^2^ every 12 hours × 5 days + cisplatin 75 mg/m^2^        50                 34

  Brandes *et al.*[@b51-co14_3p110]    [bcnu]{.smallcaps} 80 mg/m^2^, days 1--3 every 8 weeks × 6 cycles maximum                                               40                 17.5

  Brandes *et al.*[@b69-co14_3p110]    [pcb]{.smallcaps} 100 mg/m^2^ × 30 days + tamoxifen 100 mg daily                                                        51                 [na]{.smallcaps}

  Kappelle *et al.*[@b70-co14_3p110]   [pcv]{.smallcaps}                                                                                                       63                 29

  Fine *et al.*[@b71-co14_3p110]       [bcnu]{.smallcaps} 200 mg/m^2^, day 1 of every 6-week cycle + thalidomide 800 mg daily (maximum 1200 mg)                38                 27

  Brandes *et al.*[@b72-co14_3p110]    [bcnu]{.smallcaps} 100 mg/m^2^ on day 1 + irinotecan 175 mg/m^2^ weekly × 4 weeks in every 6 weeks (maximum 8 cycles)   42                 30

  Pipas *et al.*[@b73-co14_3p110]      Paclitaxel 175 mg/m^2^ day 1 + topotecan 1.0 mg/m^2^ days 1--5                                                          20                 [na]{.smallcaps}[a](#tfn2-co14_3p110){ref-type="table-fn"}

  Rich *et al.*[@b74-co14_3p110]       Gefitinib 500 mg daily; dose escalation to 750--1000 mg                                                                 53                 13

  See *et al.*[@b75-co14_3p110]        *cis-*Retinoic acid 100 mg/m^2^ daily, 21/28-day schedule                                                               85                 19

  Chang *et al.*[@b76-co14_3p110]      Temsirolimus (mTor inhibitor) 250 mg weekly                                                                             43                 2.3
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Trial suspended because of significant hemotoxicity.

[pfs]{.smallcaps} = progression-free survival; [tmz]{.smallcaps} = temozolomide; [pcb]{.smallcaps} = procarbazine; [bcnu]{.smallcaps} = 1,3-bis(2-chloroethyl)-1-nitrosourea; [na]{.smallcaps} = not available; [pcv]{.smallcaps} = procarbazine--lomustine--vincristine.
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